Obesity – Germany Drug Forecast and Market Analysis to 2022

Pages: 116 Published: October 01, 2013 Report Code: GDHC169CFR

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen
    TTS Demo

After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade.

The only drug available for the treatment of obesity in Germany is Xenical, which is seeing a steady decrease in patient use. This is a severely underserved market, as there are simply no anti-obesity drugs available. According to GlobalData’s primary research, the percentage of patients taking Xenical is extremely low at approximately only 5% of the total patients who are overweight or obese.


Overview of Obesity including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in Germany from 2012-2022.

Analysis of the impact of key events as well the drivers and restraints affecting the Germany Obesity market.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return.

Stay ahead of the competition by understanding the changing competitive landscape for Obesity.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

Make more informed business decisions from insightful and in-depth analysis of drug performance.

Obtain sales forecast for drugs from 2012-2022 in Germany.

Table of Contents

1Table of Contents1

1.1List of Tables4

1.2List of Figures6

2Executive Summary6

2.1Sales for Obesity Therapy in Germany, 2012–20226

2.2What Do the Physicians Think?7



3.2Related Reports10

3.3Upcoming Related Reports12

4Disease Overview12

4.1Etiology and Pathophysiology15




4.1.4Quality of Life17


5Disease Management17

5.1Treatment Overview17



5.2.2Clinical Practice25

6Competitive Assessment30


6.2Strategic Competitor Assessment34

6.3Product Profiles: Drugs36

6.3.1Xenical (orlistat)36

6.3.2Belviq (lorcaserin)39

6.3.3Oblean (cetilistat)44

7Opportunity and Unmet Need46


7.2A Drug with Greater Than 10% Average Weight Loss48

7.2.1Unmet Need48

7.2.2Gap Analysis48


7.3A Drug with Increased Safety and Tolerability50

7.3.1Unmet Need50

7.3.2Gap Analysis50


7.4Reimbursement by Private and Public Payers51

7.4.1Unmet Need51

7.4.2Gap Analysis52


7.5Increased Physician Education53

7.5.1Unmet Need53

7.5.2Gap Analysis54


7.6Increased Drug-Treatment Rate55

7.6.1Unmet Need55

7.6.2Gap Analysis55


7.7Improved Guidelines56

7.7.1Unmet Need56

7.7.2Gap Analysis57


7.8Improved Approach to Diagnosis57

7.8.1Unmet Need57

7.8.2Gap Analysis58


8Pipeline Assessment58


8.2Promising Drugs in Clinical Development61


8.2.2Victoza (liraglutide)69



9Market Outlook82



9.1.2Key Events88

9.1.3Drivers and Barriers89




10.3Research Methodology99

10.4Forecasting Methodology99

10.4.1Percent Drug-Treated Obesity Patients100

10.4.2Drugs Included in Each Therapeutic Class100

10.4.3Launch and Patent Expiry Dates101

10.4.4General Pricing Assumptions101

10.4.5Individual Drug Assumptions102

10.4.6Generic Erosion105

10.4.7Pricing of Pipeline Agents105

10.5Physicians, Specialists, and Payers Included in This Study106

10.6About the Authors109


10.6.2Therapy Director – CVMD and Infectious Disease110

10.6.3Director – Medical Devices110

10.6.4Global Head of Healthcare111

10.7About GlobalData112

10.8Contact Us112


List of Tables

Table 1:Target Pathways in the Treatment of Obesity16

Table 2:Symptoms of Obesity17

Table 3: Treatment Guidelines for Obesity21

Table 4: Most Prescribed Drugs for Obesity by Class in the Global Markets, 201322

Table 5: Classification of Overweight and Obesity by BMI and Waist Circumference, and the Associated Disease Risk23

Table 6:Bariatric Treatment Attributes33

Table 7: Leading Drug Treatments for Obesity, 201334

Table 8: Marketed Obesity Treatment Devices by Type35

Table 9: Product Profile – Xenical37

Table 10: Xenical SWOT Analysis, 201339

Table 11: Product Profile – Belviq41

Table 12: Belviq SWOT Analysis, 201343

Table 13: Product Profile – Oblean45

Table 14: ObleanSWOT Analysis, 201346

Table 15: Unmet Need and Opportunity in Obesity47

Table 16: Endpoint Analysis of Clinical Trials Conducted in Obesity, 201360

Table 17: Obesity – Phase II–III Pipeline, 201361

Table 18: Comparison of Therapeutic Classes in Development for Obesity, 201363

Table 19: Obesity Treatment Pipeline Devices by Type63

Table 20: Product Profile – Contrave65

Table 21: Contrave SWOT Analysis, 201368

Table 22: Product Profile – Victoza70

Table 23: Victoza SWOT Analysis, 201374

Table 24: Product Profile – Velneperit75

Table 25: Velneperit SWOT Analysis, 201378

Table 26: Product Profile – Empatic79

Table 27: Empatic SWOT Analysis, 201382

Table 28: Sales Forecasts ($) for Obesity in Germany, 2012–202286

Table 29: Key Events Impacting Sales for Obesity in Germany, 2012–202288

Table 30: Obesity Market in Germany – Drivers and Barriers, 2012–202289

Table 31: Key Launch Dates101

Table 32: Key Patent Expiries101

List of Figures

Figure 1: Sales for Obesity in Germany by Drug Class, 2012–20227

Figure 2: Treatment Algorithm for Obesity20

Figure 3: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Germany, 2012–202225

Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in Obesity, 2012–202262

Figure 5: Sales for Obesity in Germany by Drug Class, 2012–202287


Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.